Search

Veklury

Veklury

remdesivir

Manufacturer:

Gilead Sciences

Distributor:

DCH Auriga - Healthcare
/
Four Star
Concise Prescribing Info
Contents
Remdesivir
Indications/Uses
SARS-CoV-2 infections in severe patients w/ O2 saturation of ≤94% (room air), requiring supplemental O2, under extracorporeal membrane oxygenation (ECMO) introduction, or under invasive mechanical ventilation.
Click to view Veklury detailed prescribing information
Dosage/Direction for Use
Adult & ped weighing ≥40 kg Single dose of 200 mg IV on day 1 followed by once daily doses of 100 mg IV from day 2. Ped weighing 3.5-<40 kg Single dose 5 mg/kg IV on day 1, followed by 2.5 mg/kg IV from day 2. Prescribing to this patient population should only be considered if therapeutic benefits outweigh the risks. Patient on ECMO or invasive mechanical ventilation Treatment duration up to 10 days. Patient not on ECMO or invasive mechanical ventilation Treatment duration up to 5 days or until day 10 if no symptomatic improvement is observed.
Click to view Veklury detailed prescribing information
Contraindications
Hypersensitivity.
Click to view Veklury detailed prescribing information
Warnings
For additional cautionary notes to warn of the potential risk of using the medicine... Click to view Veklury detailed prescribing information
Special Precautions
Closely monitor patients by appropriate clinical & laboratory monitoring during treatment; monitor laboratory values on a daily basis. Continue administration only if it is determined that therapeutic benefits outweigh risks. Kidney & liver function tests should be performed daily before & during administration. Carefully monitor for infusion reactions; immediately discontinue administration if any abnormalities are observed. Not recommended for adults, infants, childn & adolescents w/ eGFR <30 mL/min/1.73 m2 & term newborns (7-28 days) w/ serum creatinine levels ≥1 mg/dL; patients w/ ALT levels ≥5 times the upper limit of normal range. Should only be administered in patients w/ ALT levels <5 times the upper limit of normal range if therapeutic benefits outweigh risks. Pregnancy & lactation.
Click to view Veklury detailed prescribing information
Adverse Reactions
Acute renal impairment, hepatic impairment & infusion reactions (hypotension, nausea, vomiting, sweating & tremor).
Click to view Veklury detailed prescribing information
Caution For Usage
For caution against possible variation of physical aspect of medicine... Click to view Veklury detailed prescribing information
Storage
View Veklury storage conditions for details to ensure optimal shelf-life.
Description
View Veklury description for details of the chemical structure and excipients (inactive components).
Action
View Veklury mechanism of action for pharmacodynamics and pharmacokinetics details.
MIMS Class
Antivirals
ATC Classification
J05AB16 - remdesivir ; Belongs to the class of nucleosides and nucleotides excluding reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Presentation/Packing
Form
Veklury powd for conc for soln for infusion 100 mg
Packing/Price
1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in